New research suggests the intake of the prebiotic dietary fibre oligofructose, alone or in combination with the the HMO 2’fucosyllactose, leads to substantial improvements in mood via microbiome modulation.
The US FDA has issued ‘Good Day Letters’ to dsm-firmenich for three Generally Recognized as Safe (GRAS) notices submitted for the human milk oligosaccharides (HMOs) LNFP-l/2’-FL and hypoallergenic grade LNnT and 2’-FL.
Plant-derived macronutrients are positively associated with higher pregnancy and postpartum human milk oligosaccharides (HMO) in breastmilk and could help mitigate the risk of allergies among infants, according to a study funded by Abbott Nutrition.
Individual human milk oligosaccharides (HMOs) may play critical roles in the maturation of gray matter in an infant brain, showing that inclusion of specific HMOs in infant formula could be beneficial, says a new study.
Chr. Hansen has received regulatory approval to supply a range of Human Milk Oligosaccharides (HMO) to new and existing global markets, following recent endorsements from Australia and New Zealand last year.
Infant formula’s growing ability to shift the gut microbiome closer to that of breastfed infants is outlined in a study that details how a blend of five human milk oligosaccharides (HMOs) work in tandem with each other.
A standard milk-based therapy fortified with a specific strain of gut bacteria may reduce inflammation in the infant gut and promote weight gain in infants with severe acute malnutrition, says a new study.
Belgian biotech company Inbiose, which develops human milk oligosaccharides (HMOs), has submitted its application for a Generally Recognized as Safe (GRAS) approval by the US Food & Drug Administration (FDA) of four HMOs.
Chr. Hansen has received European Commission (EC) approval to produce a novel prebiotic used in infant formula from a new microbial source, in an application that further drives the products’ premiumisation.
Supplementation with the human milk oligosaccharides (HMOs) HMOs 2'-fucosyllactose (2'FL), and lacto-N-neotetraose (LNnT) may normalize bowel function and improve bloating and IBS severity in adults, says a new study.
The potential health effects of human milk oligosaccharides (HMOs) for adults may extend beyond just promoting the growth of beneficial Bifidobacteria to also impacting immune function and the gut barrier, says a new study.
Chr. Hansen is to acquire Jennewein Biotechnologie for €310m in a deal designed to merge the bioscience firm’s probiotic interests with the gains Jennewein have made in the Human Milk Oligosaccharides (HMO) market.
Specific strains of probiotic Bifidobacterium and Lactobacillus bacteria given to preterm babies in combination with breast milk may help to build microbial populations and gut health that mirror those of full-term babies, suggests data from the Baby-Associated...
Boston-based biotech firm Conagen says it has come up with a novel and proprietary process for the scalable production of a non-GMO version of 2’-fucosyllactose (2’FL), a human milk oligosaccharide (HMO) found in human breastmilk that is becoming a sought-after...
Danone China has launched two new products for its Aptamil Essensis 3 range, including an A2 milk and a formula said to contain the highest level of human oligosaccharides (HMOs) across the firm’s entire early life nutrition portfolio.
Human Milk Oligosaccharides (HMO) such as 2’-fucosyllactose (2’-FL), and galactooligosaccharides (GOS) that are added to infant formula may offer protection against bacterium known to cause tooth decay.
Research involving Jennewein Biotechnologie suggests breast-fed infants are less likely than bottle-fed infants to contract norovirus infections, adding weight to the protective effects of Human Milk Oligosaccharides (HMOs).
The concentrations of specific human milk oligosaccharides (HMOs) in breast milk have a significant impact on growth in early childhood, and later risk of obesity, say researchers - adding that findings may inform product development and therapeutic opportunities...
A DuPont-led study outlines 2’-fucosyllactose’s (2’-FL) beneficial effect on the infant gut compared to galacto-oligosaccharides (GOS) and lactose as a team identify the oligosaccharide as a first choice energy source for selected infant microbes.
Jennewein Biotechnologie GmbH, a German company involved in the research and manufacture of human milk oligosaccharides (HMO), and Inner Mongolia Yili Industrial Group (Yili Group), China’s leading dairy company, have signed a Memorandum of Understanding...
Human milk oligosaccharides (HMOs) have extensive potential to offer a range of health benefits in products beyond infant formula, DuPont's global business director for HMOs, Steen Lyck, said at Vitafoods Asia on Tuesday.